Monoclonal Antibodies (mAbs) Products for Immunotherapy Treatment
Monoclonal antibodies (mAbs) are the largest sector in the biologics market based on revenues and drug pipelines. The clinical benefit of mAbs has been demonstrated in the treatment of autoimmune diseases and oncology.
Maintain Quality, Activity, and Stability with Avantor
Products for upstream, downstream, and drug product processing from Avantor® address the need to maintain mAbs quality, activity, and stability throughout the entire process. We match our supply chain of products for mammalian expression systems to meet the complexity of monoclonal antibody manufacturing, from process development and scale-up to commercial manufacturing to final fill.
J.T.Baker® BAKERBOND® PROchievA™ protein A chromatography resins
From discovery to delivery, you can trust Avantor® to provide the mAbs products and tools you need to streamline your workflow and improve your processes. We carry thousands of antibodies, high-yield antibody purification buffers, and immunotherapeutic support to help you drive discovery.
What Are Monoclonal Antibodies?
Monoclonal antibodies, also called mAbs, are proteins made in a laboratory that act identically to immune system antibodies. These manufactured antibodies come from a single unique parent cell and are exact replicas of antibodies that target one specific antigen. That makes them ideal for targeted monoclonal antibodies immunotherapy.
Among the uses for monoclonal antibodies are the treatment diseases, including:
- Autoimmune diseases
- Viral infections, such as Ebola and COVID-19
Monoclonal antibodies are used for a variety of diagnostic procedures that include:
- Lymphoid and myeloid malignancies
- Tissue typing
- Enzyme-linked immunosorbent assay
- Serotyping of microorganisms
- Immunological intervention with passive antibody
- Anti-idiotype inhibition
How Do Monoclonal Antibodies Work?
Monoclonal antibodies (mAbs) work in a variety of ways depending on the protein they are targeting. Each mAb mimics one of the body’s natural antibodies and functions as immunotherapy by targeting one particular protein to:
- Trigger the immune system
- Help the immune system
- Block signals or target another aspect of the cell
Future of Monoclonal Antibodies Treatment
Monoclonal antibodies (mAbs) are the largest sector in the biologics market, based on revenues and drug pipelines. The clinical benefit of mAbs has been effective in treating autoimmune diseases and oncology.
Significant investments are now focusing on developing mAbs for the growing field of immuno-oncology or monoclonal antibodies immunotherapy. Efforts include process optimization to increase mAb titers, mAb fragments manufactured in other expression systems, multiple target specificity for mAbs, and the development of Antibody-Drug Conjugates (ADCs) that deliver highly toxic drugs to targeted cancer cells.